TerminatedPhase 2NCT00863434

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Pamela Becker
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Intervention
clofarabine(drug)
Enrollment
2 enrolled
Eligibility
18-75 years · All sexes
Timeline
2009

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00863434 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials